Advisors Asset Management’s Corcept Therapeutics CORT Stock Holding History

Advisors Asset Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$408K	Sell	10,118 -1,908	-16%	-$71.3K	0.01%	1010
2025 Q4	$419K	Sell	12,026 -5,189	-30%	-$408K	0.01%	1001
2025 Q3	$1.43M	Sell	17,215 -1,720	-9%	-$124K	0.02%	695
2025 Q2	$1.39M	Buy	18,935 +237	+1%	+$17.2K	0.02%	672
2025 Q1	$2.14M	Buy	18,698 +2,607	+16%	+$159K	0.04%	541
2024 Q4	$811K	Buy	16,091 +3,430	+27%	+$180K	0.01%	798
2024 Q3	$586K	Buy	12,661 +2,897	+30%	+$103K	0.01%	891
2024 Q2	$317K	Buy	9,764 +4,177	+75%	+$114K	0.01%	1008
2024 Q1	$141K	Buy	5,587 +5,055	+950%	+$119K	﹤0.01%	1185
2023 Q4	$17.3K	Buy	+532	New	+$14.6K	﹤0.01%	1362

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Advisors Asset Management's CORT Position: Q1 2026 in Review

Advisors Asset Management reduced its Corcept Therapeutics (CORT) stake by 16% in Q1 2026, selling an estimated $71.3K and leaving 10,118 shares worth $408K. The position accounts for 0.01% of the portfolio, ranked #1010.

Advisors Asset Management first reported a position in CORT in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.14M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Advisors Asset Management held 10,118 shares of Corcept Therapeutics worth $408K as of Q1 2026.
Advisors Asset Management sold 1,908 Corcept Therapeutics shares in Q1 2026, an estimated $71.3K.
Corcept Therapeutics made up 0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1010 holding.
Advisors Asset Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 10 quarters since.
Advisors Asset Management's Corcept Therapeutics position peaked at $2.14M in Q1 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.